Biologic agents, such as TNF inhibitors and IL-17 inhibitors, have revolutionized the treatment of ARDs by targeting specific inflammatory pathways; however, not all patients respond to these agents, and many patients experience a loss of response over time. Here, TNF is linked to acute respiratory distress syndrome.